- Home
- Companies
- us virgin islands
- neurodegeneration disorder
Refine by
Neurodegeneration Disorder Suppliers Serving Us Virgin Islands
10 companies found
based inBingham, MICHIGAN (USA)
In 2017, a group of internationally-recognized MRI industry professionals and entrepreneurs founded SpinTech, Inc. with the goal of transforming advanced MRI techniques, previously reserved only for the research realm, into practical applications to ...
based inCAEN, FRANCE
Lys Therapeutics, first-in-class biotherapies against neurological diseases. Lys Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from neurovascular or neurodegenerative disorders, including stroke and ...
Glunomab / Glunozumab®: a monoclonal antibody counteracting the strong toxicity triggered by the interaction of an endogenous protease, tissue plasminogen activator (tPA) with NMDA receptors ...
based inLynnwood, WASHINGTON (USA)
Kurve Therapeutics drug delivery technology is designed to target the most difficult part of the treatment process - getting medication through the blood-brain barrier and into the brain. Kurve Therapeutics has 18 peer-reviewed publications of ...
based inGeneva, SWITZERLAND
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric ...
mGlu3 PAM for the treatment of neurodegenerative disorders. We are developing mGlu3 PAM as a novel orally available treatment for neurodegenerative disorders. We are currently optimizing multiple chemical series of highly selective mGlu3 PAMs, with ...
based inDublin 4, IRELAND
Alkermes is focused on developing innovative medicines that aim to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated global biopharmaceutical company, we apply our scientific expertise and ...
based inVerona, ITALY
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...
The PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology, of which Sibylla is the exclusive licensee, is a paradigm shift in rational drug design. The basic task of drug design is to find a small molecule able ...
based inStockholm, SWEDEN
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as disease modifiers. They ...
BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease. Our mission is to improve quality of life for patients ...
based inToronto, ONTARIO (CANADA)
Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI. Programming RNA Therapies Any Gene, Any Genetic Condition. Revolutions in AI, RNA biology and automation ...
based inProvidence, RHODE ISLAND (USA)
A spinout of Oxford University, founded by a global team of experienced entrepreneurs, technologists, and neuroscientists, ni2o is continuing the work started by MIT’s Mind Machine Project – developing a revolutionary brain-computer interface (BCI) ...
based inWoburn, MASSACHUSETTS (USA)
As the scientific leader in the biological role of the microbiome gut-brain axis and its impact on neurological conditions, Axial Therapeutics is uniquely positioned to advance a fundamentally different therapeutic approach for the treatment of ...